<DOC>
	<DOCNO>NCT00689884</DOCNO>
	<brief_summary>The purpose study determine efficacy Pegfilgrastim mobilization autologous peripheral blood stem cell ( PBSCs ) , define cell yield â‰¥ 3 x 10e6 CD34+/kg ass cost related Pegfilgrastim use mobilization autologous PBSCs . Also determine side effect Pegfilgrastim mobilization autologous peripheral blood stem cell .</brief_summary>
	<brief_title>Feasibility Cost Analysis PBSC Mobilization Using Pegfilgrastim Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . All patient hematologic malignancy undergo stem cell mobilization association chemotherapy , prior autologous stem cell transplantation . 2 . Prior Treatment : No parenteral cytotoxic chemotherapy within 2 week prior initiation chemomobilization therapy . 3 . Performance Status : Karnofsky &gt; 70 % 4 . Age &gt; 18 5 . Life Expectancy &gt; 4 month 6 . Bone Marrow : bone marrow biopsy aspirate 7 . Blood count : The patient must adequate bone marrow function , i.e . total WBC &gt; 2,000/ul , Hgb &gt; 7 g/dl , platelet count &gt; 50,000/ul , unless abnormality believe due underlying disease . 8 . Pulmonary function test : DLCO &gt; 55 % predict . 9 . Cardiac : Left ventricular ejection fraction &gt; 40 % radionuclide scan echocardiography . 10 . Liver function test ( bilirubin , alkaline phosphatase , SGOT/SGPT ) &lt; 3 x normal ( unless believe elevate due disease ) . 11 . Renal function ( 24 hour urine creatinine clearance , clinically indicate ) : The patient must adequate renal function ( creatinine clearance &gt; 50 ml/min ) , except renal insufficiency felt related underlying malignancy . 12 . No significant comorbid medical psychiatric illness would significantly compromise patient 's clinical care chance survival transplant setting . 13 . No significant establish splenomegaly ( i.e . spleen size &gt; 20 cm ) 14 . Informed write consent must obtain . Patients must able give informed consent prerequisite procedure . The Informed Consent form become part his/her permanent record copy give patient . 1 . Patients great three pretransplant chemotherapy regimens and/or poor stem cell reserve demonstrate significant marrow hypocellularity ( &lt; 20 % ) mobilize first phase regimen 2 . Medical , social , psychological factor would prevent patient receive cooperate full course therapy . 3 . Evidence physical exam , LP , CT , MRI scan CNS involvement malignancy . 4 . Uncontrolled severe cardiovascular disease , include recent ( &lt; 6 month ) myocardial infarction , congestive heart failure , angina ( symptomatic despite optimal medical management ) , lifethreatening dysrhythmia , clinically significant obstructive/restrictive pulmonary disease . 5 . Serology positive HIV . 6 . Positive pregnancy test presence lactation . 7 . Uncontrolled active infection . 8 . Documented hypersensitivity drug use protocol . 9 . No concomitant , ongoing malignancy lifethreatening , base PI 's evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>